Guided Therapeutics (GTHP) Shares Outstanding (Weighted Average) (2010 - 2025)

Guided Therapeutics has disclosed Shares Outstanding (Weighted Average) across 16 years of filings, most recently posting $78.4 million for Q4 2025.

• Shares Outstanding (Weighted Average) for Q4 2025 came in at $78.4 million, up 36.76% year-over-year; the trailing twelve-month figure through Dec 2025 was $78.4 million (up 36.76% YoY), and the FY2025 annual result was $78.4 million, up 36.76% from the prior year.
• Shares Outstanding (Weighted Average) came in at $78.4 million for Q4 2025 at Guided Therapeutics, up from $76.4 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $78.4 million in Q4 2025 to a low of $49297.0 in Q1 2023.
• The 5-year median for Shares Outstanding (Weighted Average) is $28.9 million (2023), against an average of $35.5 million.
• Across the five-year window, Shares Outstanding (Weighted Average) jumped 262656.83% in 2021 and slumped 99.76% in 2023, its largest moves.
• Guided Therapeutics' Shares Outstanding (Weighted Average) stood at $13.4 million in 2021, then soared by 166.03% to $35.6 million in 2022, then dropped by 19.68% to $28.6 million in 2023, then jumped by 100.59% to $57.3 million in 2024, then soared by 36.76% to $78.4 million in 2025.
• The last three Shares Outstanding (Weighted Average) figures came in at $78.4 million (Q4 2025), $76.4 million (Q3 2025), and $73.6 million (Q2 2025), per Business Quant data.